In an era of personalization — where music apps filter songs based on listener preferences and online ads populated based on user search history — healthcare is the next frontier.
Scientific advances are transforming healthcare and ushering in a new era of personalized – or precision – medicine. This approach makes it possible to account for each patient’s genetics, health history and lifestyle as researchers develop and doctors prescribe individualized treatments.
Such data-driven medicine has far-reaching policy implications, from regulations to delivery systems.
On October 22nd, join The Hill for a discussion on the impact of this emerging field, the challenges to its progress, and how the Precision Medicine Initiative fits into the complex personalized medicine ecosystem.
8:35 AM – Sponsor perspective, presented by JOHN J. CASTELLANI, President and CEO, PhRMA
8:45 AM – Thought-leader roundtable, moderated by The Hill’s Sarah Ferris and featuring:
ALAN BALCH, Ph.D., CEO, Patient Advocate Foundation and National Patient Advocate Foundation
STEVEN D. AVERBUCH, M.D., Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb
AMY MILLER, Ph.D., Executive VP, Personalized Medicine Coalition
9:25 AM – 2:1 Keynote conversation, moderated by The Hill’s Bob Cusack and featuring:
KATHY HUDSON, Ph.D., Deputy Director for Science, Outreach and Policy, National Institutes of Health [NIH]
ELIZABETH MANSFIELD, Ph.D., Director of Personalized Medicine in the Office of In Vitro Diagnostics Device Evaluation & Safety, Center for Devices and Radiological Health, Food & Drug Administration [FDA]
9:45 AM – Program concludes
Sponosored by
